Abstract:ObjectiveTo investigate the clinical effect of Levofloxacin in the treatment of pulmonary tuberculosis.Methods200 cases of tuberculosis patients treated in our hospital from December 2014 to December 2016 were selected as the study subjects,and randomly divided into observation group and control group by different treatments,100 cases in each group.Patients in the control group were treated with Isoniazid,Rifampicin,Pyrazinamide and Ethambutol.Patients in the observation group were treated with Levofloxacin based on the treatment of control group.The improvement of the symptoms,the cases of sputum negative conversion,absorption of the lung lesions and the adverse reactions of the two groups were compared.ResultsAt 1 month after treatment,the symptom improvement rate in observation group (54%)was significantly higher than that in control group (38%).At 6 months after treatment,the symptom improvement rate in observation group (91%)was significantly higher than that in control group (74%).1 month after treatment,the sputum negative conversion rate in the observation group(91%)was significantly higher than that in the control group(79%).After 6 months,the sputum negative conversion rate in observation group(100%)was significantly higher than that in the control group(85%).The lung absorption rate in the observation group(94%)was higher than that in the control group(73%).The incidence of dverse reactions in the observation group(20%)was significantly lower than the control group(49%),the difference was statistically significant(P<0.05).ConclusionLevofloxacin in patients with pulmonary tuberculosis can significantly improve clinical efficacy,effectively improve the symptoms of patients,improve sputum negative conversion rate and intrapulmonary lesions absorption rate,reduce the risk of adverse reactions,have a wide range of applications,whicht is worthy of clinical promotion and application.